SG11201504204XA - Hydantoin derivative - Google Patents

Hydantoin derivative

Info

Publication number
SG11201504204XA
SG11201504204XA SG11201504204XA SG11201504204XA SG11201504204XA SG 11201504204X A SG11201504204X A SG 11201504204XA SG 11201504204X A SG11201504204X A SG 11201504204XA SG 11201504204X A SG11201504204X A SG 11201504204XA SG 11201504204X A SG11201504204X A SG 11201504204XA
Authority
SG
Singapore
Prior art keywords
hydantoin derivative
hydantoin
derivative
Prior art date
Application number
SG11201504204XA
Other languages
English (en)
Inventor
Yoshikazu Nishimura
Toru Esaki
Tatsuya Tamura
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG11201504204XA publication Critical patent/SG11201504204XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201504204XA 2012-12-10 2013-12-10 Hydantoin derivative SG11201504204XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012269178 2012-12-10
PCT/JP2013/083022 WO2014092061A1 (ja) 2012-12-10 2013-12-10 ヒダントイン誘導体

Publications (1)

Publication Number Publication Date
SG11201504204XA true SG11201504204XA (en) 2015-07-30

Family

ID=50934349

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504204XA SG11201504204XA (en) 2012-12-10 2013-12-10 Hydantoin derivative

Country Status (35)

Country Link
US (5) US9428505B2 (zh)
EP (1) EP2930176B1 (zh)
JP (1) JP5951799B2 (zh)
KR (1) KR102168738B1 (zh)
CN (1) CN104854106B (zh)
AU (1) AU2013358167B2 (zh)
BR (1) BR112015012411B1 (zh)
CA (1) CA2892621C (zh)
CL (2) CL2015001391A1 (zh)
CR (1) CR20150272A (zh)
DK (1) DK2930176T3 (zh)
ES (1) ES2663797T3 (zh)
HK (1) HK1209735A1 (zh)
HR (1) HRP20180647T1 (zh)
HU (1) HUE037530T2 (zh)
IL (1) IL238277B (zh)
LT (1) LT2930176T (zh)
MA (1) MA38250B1 (zh)
MX (1) MX2015007309A (zh)
MY (1) MY178583A (zh)
NO (1) NO2930176T3 (zh)
NZ (1) NZ707946A (zh)
PE (1) PE20151295A1 (zh)
PH (1) PH12015501146B1 (zh)
PL (1) PL2930176T3 (zh)
PT (1) PT2930176T (zh)
RS (1) RS57190B1 (zh)
RU (1) RU2678984C2 (zh)
SA (1) SA515360528B1 (zh)
SG (1) SG11201504204XA (zh)
SI (1) SI2930176T1 (zh)
TW (1) TWI615394B (zh)
UA (1) UA115072C2 (zh)
WO (1) WO2014092061A1 (zh)
ZA (1) ZA201503597B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525353T3 (es) 2009-04-28 2014-12-22 Chugai Seiyaku Kabushiki Kaisha Derivado de espiroimidazolona
KR102168738B1 (ko) * 2012-12-10 2020-10-22 추가이 세이야쿠 가부시키가이샤 히단토인 유도체
MX371090B (es) * 2014-06-09 2020-01-16 Chugai Pharmaceutical Co Ltd Composicion farmaceutica que contiene derivado de hidantoina.
CN112770750A (zh) * 2018-07-30 2021-05-07 中外制药株式会社 乙内酰脲衍生物的固体分散体
CN110464002A (zh) * 2019-09-12 2019-11-19 西南石油大学 一种天然冰粉的制备方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135470A (ja) 1997-07-23 1999-02-09 Teijin Ltd ビタミンd3誘導体を含有する副甲状腺ホルモン産生促進剤
AU765729B2 (en) 1998-12-11 2003-09-25 F. Hoffmann-La Roche Ag Cyclic hydrazine derivatives as TNF-alpha inhibitors
US7004593B2 (en) * 2002-06-06 2006-02-28 Donnelly Corporation Interior rearview mirror system with compass
CA2420759A1 (en) 2000-08-30 2003-02-27 Daishiro Miura Parathyroid hormone production inhibitors containing vitamin d3 derivatives
AU2002210813A1 (en) * 2000-10-26 2002-05-06 Pfizer Products Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
WO2005077959A1 (en) 2004-02-11 2005-08-25 Smithkline Beecham Corporation Pth agonists
EP1713782A4 (en) 2004-02-11 2009-11-11 Smithkline Beecham Corp PTH AGONISTS
CN101072771B (zh) 2004-10-07 2010-09-29 默沙东公司 Cgrp受体拮抗剂
WO2007135417A1 (en) 2006-05-19 2007-11-29 James Black Foundation Benzotriazepinone derivatives
JP2009541342A (ja) 2006-06-20 2009-11-26 ワイス Kv1.5カリウムチャネル阻害剤
CN101679241B (zh) 2007-06-07 2012-06-27 弗·哈夫曼-拉罗切有限公司 作为nk3拮抗剂的脯氨酰胺衍生物
CN101939054B (zh) 2007-12-10 2014-10-29 诺华股份有限公司 有机化合物
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
WO2010045229A2 (en) 2008-10-13 2010-04-22 University Of Rochester Protecting and repairing cartilage and musculoskeletal soft tissues
ES2525353T3 (es) * 2009-04-28 2014-12-22 Chugai Seiyaku Kabushiki Kaisha Derivado de espiroimidazolona
KR102168738B1 (ko) * 2012-12-10 2020-10-22 추가이 세이야쿠 가부시키가이샤 히단토인 유도체
MX371090B (es) * 2014-06-09 2020-01-16 Chugai Pharmaceutical Co Ltd Composicion farmaceutica que contiene derivado de hidantoina.

Also Published As

Publication number Publication date
JP5951799B2 (ja) 2016-07-13
ZA201503597B (en) 2016-09-28
BR112015012411A2 (pt) 2017-07-11
SI2930176T1 (en) 2018-06-29
US20210024524A1 (en) 2021-01-28
CL2015001391A1 (es) 2015-07-31
NO2930176T3 (zh) 2018-07-07
US20150274727A1 (en) 2015-10-01
US20160326175A1 (en) 2016-11-10
EP2930176A4 (en) 2016-06-01
HRP20180647T1 (hr) 2018-06-01
PH12015501146A1 (en) 2015-08-10
HK1209735A1 (zh) 2016-04-08
TW201439092A (zh) 2014-10-16
CA2892621A1 (en) 2014-06-19
CN104854106B (zh) 2017-07-04
US20180237436A1 (en) 2018-08-23
PH12015501146B1 (en) 2015-08-10
RU2015127624A (ru) 2017-01-16
DK2930176T3 (en) 2018-03-19
CR20150272A (es) 2015-07-09
US9428505B2 (en) 2016-08-30
TWI615394B (zh) 2018-02-21
IL238277A0 (en) 2015-06-30
BR112015012411B1 (pt) 2021-10-05
LT2930176T (lt) 2018-04-10
MA38250B1 (fr) 2017-10-31
EP2930176B1 (en) 2018-02-07
MY178583A (en) 2020-10-16
MX2015007309A (es) 2015-09-10
NZ707946A (en) 2019-11-29
IL238277B (en) 2018-01-31
SA515360528B1 (ar) 2018-05-24
CL2017000069A1 (es) 2017-08-25
AU2013358167A1 (en) 2015-04-09
CA2892621C (en) 2021-02-16
UA115072C2 (uk) 2017-09-11
AU2013358167B2 (en) 2017-09-14
MA38250A1 (fr) 2017-02-28
JPWO2014092061A1 (ja) 2017-01-12
RS57190B1 (sr) 2018-07-31
PT2930176T (pt) 2018-04-03
PL2930176T3 (pl) 2018-07-31
CN104854106A (zh) 2015-08-19
RU2678984C2 (ru) 2019-02-05
HUE037530T2 (hu) 2018-09-28
PE20151295A1 (es) 2015-10-10
WO2014092061A1 (ja) 2014-06-19
KR102168738B1 (ko) 2020-10-22
ES2663797T3 (es) 2018-04-17
KR20150092275A (ko) 2015-08-12
US20220162208A1 (en) 2022-05-26
EP2930176A1 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
HUS2200040I1 (hu) Benzimidazol-prolin származékok
HK1205740A1 (zh) 吡咯並三嗪酮衍生物
HK1207375A1 (zh) 呱啶基吡唑並吡啶衍生物
HK1207363A1 (zh) 新型茚滿磺酰胺衍生物
HK1209115A1 (zh) 咪唑衍生物
AP2015008347A0 (en) Oxazolidin-2-one-pyrimidine derivatives
HRP20180647T1 (hr) Derivat hidantoina
HK1200824A1 (zh) 被取代的苯基唑衍生物
PT2873660T (pt) Derivado de indolecarboxamida
EP2703403A4 (en) imidazole
EP2842958A4 (en) NAPHTHOBISTHIADIAZOLDERIVAT
HK1204621A1 (zh) -烷酰基氨基- -吡唑啉酮衍生物